Effect of montelukast on the expression of interleukin-18, telomerase reverse transcriptase, and Bcl-2 in the brain tissue of neonatal rats with hypoxic-ischemic brain damage

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 8901-8908

  Liu, J L ^a,b   Zhao, X H ^b   Zhang, D L ^c   Zhang, J B ^b   Liu, Z H ^b  

^a SHANDONG UNIVERSITY   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

^c Department of Encephalopathy   (China)

Author keywords

Bcl 2; Hypoxic ischemic brain injury; IL 18; Montelukast; Rat brain tissue; TERT

Indexed keywords

INTERLEUKIN 18; MONTELUKAST; OXYGEN; PROTEIN BCL 2; SODIUM CHLORIDE; TELOMERASE REVERSE TRANSCRIPTASE; ACETIC ACID DERIVATIVE; QUINOLINE DERIVATIVE; TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; BRAIN TISSUE; CAROTID ARTERY LIGATION; CONTROLLED STUDY; DRUG EFFICACY; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOHISTOCHEMISTRY; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; BIOSYNTHESIS; CASE CONTROL STUDY; DISEASE MODEL; HYPOXIA-ISCHEMIA, BRAIN; METABOLISM;

RATTUS;

ACETATES; ANIMALS; ANIMALS, NEWBORN; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; HYPOXIA-ISCHEMIA, BRAIN; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-18; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOLINES; RATS; TELOMERASE;

EID: 84938650855     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.August.3.13     Document Type: Article

References (20)

1. Bukstein DA, Henk HJ and Luskin AT (2001), A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy, Clin, Ther, 23: 1589-1600.
2. Chen X, Cheng D, Guan J, Xia X, et al, (2003), Preventive effects of montelukast on hypoxic pulmonary hypertension in rats, Sichuan Da Xue Xue Bao Yi Xue Ban 34: 555-558.
3. Cheng H, Leff JA, Amin R, Gertz BJ, et al, (1996), Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females, Pharm, Res, 13: 445-448.
4. Del Bufalo D, Rizzo A, Trisciuoglio D, Cardinali G, et al, (2005), Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function, Cell Death, Differ, 12: 1429-1438.
5. Karonen T, Neuvonen PJ and Backman JT (2012), CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast, Br J, Clin, Pharmacol, 73: 257-267.
6. Kita T, Fujimura M, Ogawa H, Nakatsumi Y, et al, (2010), Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough, Allergol, Int, 59: 185-192.
7. Kose E, Sapmaz HI, Sarihan E, Vardi N, et al, (2012), Beneficial effects of montelukast against methotrexate-induced liver toxicity: a biochemical and histological study, Sci, World J, 2012: 987-508.
8. Lu S, Liu N, Dass SB and Reiss TF (2009), A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma, J, Asthma 46: 465-469.
9. Matsunaga K, Hirano T, Nakanishi M, Yamagata T, et al, (2008), Effect of a leukotriene receptor antagonist on the prevention of recurrent asthma attacks after an emergency room visit, Allergol, Int, 53: 341-347.
10. Moulder JE and Rockwell S (1984), Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data, Int, J, Radiat, Oncol, Biol, Phys, 10: 695-712.
11. Philip G, Pedinoff A, Vandormael K, Tymofyeyev Y, et al, (2010), A phase I randomized, placebo-controlled, doseexploration study of single-dose inhaled montelukast in patients with chronic asthma, J, Asthma 47: 1078-1084.
12. Rice JE 3rd, Vannucci RC and Brierley JB (1981), The influence of immaturity on hypoxic-ischemic brain damage in the rat, Ann, Neurol, 9: 131-141.
13. Selway LD (2010), State of the science: hypoxic ischemic encephalopathy and hypothermic intervention for neonates, Adv, Neonatal, Care 10: 60-66.
14. Stanford RH, Shah M and D’Souza AO (2013), Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma, J, Asthma Allergy 6: 1-10.
15. Stelmach I, Jerzynska J and Kuna P (2002), A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma, J, Allergy Clin.Immunol, 109: 257-263.
16. Szefler SJ, Carlsson LG, Uryniak T and Baker JW (2013), Budesonide inhalation suspension versus montelukast in children aged 2 to 4 years with mild persistent asthma, J, Allergy Clin, Immunol, Pract, 1: 58-64.
17. van Velthoven CT, Kavelaars A and Heijnen CJ (2012), Mesenchymal stem cells as a treatment for neonatal ischemic brain damage, Pediatr, Res, 71: 474-481.
18. Yu GL, Wei EQ, Zhang SH, Xu HM, et al, (2005), Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice, Pharmacology 73: 31-40.
19. Zhang SH, Wei EQ, Zhu CY, Chen Z, et al, (2004), Protective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia induced by endothelin-1 in rats, Yao Xue Xue Bao 39: 1-4.
20. Zhao JJ, Rogers JD, Holland SD, Larson P, et al, (1997), Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers, Biopharm, Drug Dispos, 18: 769-777